The pharma giant will lose its patent protection on semaglutide, which is sold as Ozempic and Wegovy, in Canada after not ...

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy.The stock is up ...

Novo Nordisk A/S (NYSE:NVO) is among the best bear market stocks to buy according to analysts. Novo Nordisk A/S (NYSE:NVO) has reclaimed its crown as Europe’s most valuable publicly traded company, ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

Nvidia (NVDA, Financials) said Tuesday it is partnering with Novo Nordisk to accelerate drug discovery using its generative ...

Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...

Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German software firm SAP ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...